MBLX Metabolix Inc

Yield10 Bioscience Announces Closing of $11.5 Million Equity Offering and Full Exercise of Over-allotment Option

Yield10 Bioscience Announces Closing of $11.5 Million Equity Offering and Full Exercise of Over-allotment Option

WOBURN, Mass., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries, announced today the closing of an equity offering, which consisted of an underwritten public offering of units and a private placement of units for gross proceeds of $11.5 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by Yield10 Bioscience. Both existing investors, including 40.1% shareholder Jack W. Schuler, and new institutional investors participated in the offering.

Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT:LTS), is sole book-running manager and placement agent in connection with the public offering and the private placement.

The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-233683), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on November 14, 2019.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A final prospectus relating to the public offering was filed by Yield10 Bioscience with the SEC. Copies of the final prospectus can be obtained at the SEC’s website at  or from Ladenburg Thalmann & Co. Inc., Prospectus Department, 277 Park Avenue, 26th Floor, New York, New York 10172, by calling (212) 409-2000. 

About Yield10

Yield10 Bioscience, Inc. is an agricultural bioscience company which uses its “Trait Factory” to develop high value seed traits for the agriculture and food industries to achieve step-change improvements in crop yield to enhance global food security and develop specialty crop products. Yield10 has an extensive track record of innovation based around optimizing the flow of carbon in living systems. Yield10 is leveraging its “GRAIN” technology platform and unique knowledge base to design precise alterations to gene activity and the flow of carbon in plants to produce higher yields with lower inputs of land, water or fertilizer. Yield10 is advancing several yield traits it has developed in crops such as canola, soybean, rice, wheat and corn. Yield10 is headquartered in Woburn, MA and has an Oilseeds Center of Excellence in Saskatoon, Canada.

For more information about the Company, please visit .   (YTEN-G)

Contacts: 

Yield10 Bioscience:

Lynne H. Brum, (617) 682-4693,

Investor Relations: 

Bret Shapiro, (516) 222-2560,

Managing Director, CORE IR

Media Inquiries:

Eric Fischgrund,

FischTank Marketing and PR

EN
19/11/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Metabolix Inc

 PRESS RELEASE

Yield10 Bioscience Announces Second Quarter 2024 Financial Results

Yield10 Bioscience Announces Second Quarter 2024 Financial Results WOBURN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the second quarter ended June 30, 2024. "We continue to work closely with the Nufarm team to finalize the asset purchase agreement announced in July,” said Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10. “We believe that the transition of our Omega-3 Camelina program to Nufarm is in the best interest of our sh...

 PRESS RELEASE

Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Asset...

Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets - Nufarm to pay up to USD $5 million in consideration for the license-The parties will negotiate the sale of essentially all of Yield10’s assets to Nufarm WOBURN, Mass. and WEST SACRAMENTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company has signed a Memorandum of Understanding (“MOU”...

 PRESS RELEASE

Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Com...

Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in Camelina Engineered Camelina is intended to enable the land-based production of omega-3 oils used in aquafeed, petfood and human nutrition WOBURN, Mass. and HARPENDEN, United Kingdom, June 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that U.K.-based Rothamsted Research Limited (“Rothamsted”) has granted to the Company an exclusive global, commerc...

 PRESS RELEASE

Yield10 Bioscience Announces Addition of Camelina to INTERLINE® Herbic...

Yield10 Bioscience Announces Addition of Camelina to INTERLINE® Herbicide Label - EPA approved an amendment to the label of INTERLINE herbicideto include Camelina -The supplemental label now allows application of INTERLINE for over-the-top weed control in Camelina WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that UPL Ltd. (“UPL”) has received U.S. Environmental Protection Agency (“EPA”) approval to of INTERLINE® Herbicide to include the oilseed Camelina sativa (“Came...

 PRESS RELEASE

Yield10 Bioscience Announces First Quarter 2024 Financial Results

Yield10 Bioscience Announces First Quarter 2024 Financial Results -Earns $1 million in milestone payments from Vision Bioenergy Oilseeds WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the first quarter ended March 31, 2024. "In the first quarter of 2024, we made the strategic decision to focus our resources on the commercialization of Camelina products targeting the aquafeed and nutritional markets for omega-3 fatty acids," said Oliver Peoples, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch